CN115804821A - 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 - Google Patents
寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 Download PDFInfo
- Publication number
- CN115804821A CN115804821A CN202211635736.7A CN202211635736A CN115804821A CN 115804821 A CN115804821 A CN 115804821A CN 202211635736 A CN202211635736 A CN 202211635736A CN 115804821 A CN115804821 A CN 115804821A
- Authority
- CN
- China
- Prior art keywords
- asthma
- hormone
- particles
- daphne
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 131
- 239000005556 hormone Substances 0.000 title claims abstract description 75
- 229940088597 hormone Drugs 0.000 title claims abstract description 75
- 239000008187 granular material Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 40
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 34
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 20
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 20
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract description 20
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 20
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims abstract description 17
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims abstract description 17
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims abstract description 16
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims abstract description 16
- 210000002175 goblet cell Anatomy 0.000 claims abstract description 14
- 210000003097 mucus Anatomy 0.000 claims abstract description 10
- 230000028327 secretion Effects 0.000 claims abstract description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 15
- 210000003979 eosinophil Anatomy 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 6
- 210000004969 inflammatory cell Anatomy 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 210000000621 bronchi Anatomy 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 201000010659 intrinsic asthma Diseases 0.000 claims description 4
- 241000736299 Adiantum Species 0.000 claims description 3
- 240000006054 Agastache cana Species 0.000 claims description 3
- 240000006927 Foeniculum vulgare Species 0.000 claims description 3
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 3
- 235000010650 Hyssopus officinalis Nutrition 0.000 claims description 3
- 241000220317 Rosa Species 0.000 claims description 3
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 3
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 3
- 244000274883 Urtica dioica Species 0.000 claims description 3
- 235000009108 Urtica dioica Nutrition 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 239000001387 apium graveolens Substances 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 3
- 240000004784 Cymbopogon citratus Species 0.000 claims description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 235000011477 liquorice Nutrition 0.000 claims description 2
- 241001163443 Daphne giraldii Species 0.000 abstract description 9
- 206010020718 hyperplasia Diseases 0.000 abstract description 6
- 230000002018 overexpression Effects 0.000 abstract description 5
- 208000037883 airway inflammation Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 241000934856 Daphne Species 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 239000003862 glucocorticoid Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000036065 Airway Remodeling Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 210000005091 airway smooth muscle Anatomy 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000031337 regulation of inflammatory response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010021133 Hypoventilation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 235000003976 Ruta Nutrition 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- -1 ambroxol Chemical compound 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960001951 montelukast sodium Drugs 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000005806 ruta Nutrition 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211635736.7A CN115804821B (zh) | 2022-12-19 | 2022-12-19 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211635736.7A CN115804821B (zh) | 2022-12-19 | 2022-12-19 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115804821A true CN115804821A (zh) | 2023-03-17 |
CN115804821B CN115804821B (zh) | 2024-05-14 |
Family
ID=85486305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211635736.7A Active CN115804821B (zh) | 2022-12-19 | 2022-12-19 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115804821B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60045240D1 (de) * | 1999-03-02 | 2010-12-30 | Centocor Inc | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
WO2016009253A1 (en) * | 2014-07-16 | 2016-01-21 | Anil Mishra | Recombinant interleukin-15 is a therapeutic agent for the treatment of airway hyperactivity, resistance (obstruction) and fibrosis in chronic asthma |
CN106692716A (zh) * | 2015-08-05 | 2017-05-24 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒的医药新用途 |
WO2019124666A2 (ko) * | 2017-12-19 | 2019-06-27 | 포항공과대학교 산학협력단 | 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물 |
CN114177216A (zh) * | 2021-11-30 | 2022-03-15 | 华中科技大学 | 神香草挥发油的分析方法及在制备治疗激素抵抗性哮喘药物中的应用 |
-
2022
- 2022-12-19 CN CN202211635736.7A patent/CN115804821B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60045240D1 (de) * | 1999-03-02 | 2010-12-30 | Centocor Inc | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
PT1159003E (pt) * | 1999-03-02 | 2011-02-22 | Centocor Inc | Anti-tnf alfa na terapêutica da asma resistente a esteróides |
WO2016009253A1 (en) * | 2014-07-16 | 2016-01-21 | Anil Mishra | Recombinant interleukin-15 is a therapeutic agent for the treatment of airway hyperactivity, resistance (obstruction) and fibrosis in chronic asthma |
CN106692716A (zh) * | 2015-08-05 | 2017-05-24 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒的医药新用途 |
WO2019124666A2 (ko) * | 2017-12-19 | 2019-06-27 | 포항공과대학교 산학협력단 | 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물 |
CN114177216A (zh) * | 2021-11-30 | 2022-03-15 | 华中科技大学 | 神香草挥发油的分析方法及在制备治疗激素抵抗性哮喘药物中的应用 |
Non-Patent Citations (2)
Title |
---|
余元勋等: "《中国分子支气管哮喘病学》", pages: 19 - 20 * |
余通等: "维吾尔药寒喘祖帕颗粒研究进展及临床应用", 《新中医》, pages 6 - 8 * |
Also Published As
Publication number | Publication date |
---|---|
CN115804821B (zh) | 2024-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021189753A1 (zh) | 扶正救肺药物组合物及其应用 | |
Wei et al. | Astragalus membranaceus improves therapeutic efficacy of asthmatic children by regulating the balance of Treg/Th17 cells | |
Han et al. | Paeoniflorin ameliorates airway inflammation and immune response in ovalbumin induced asthmatic mice: From oxidative stress to autophagy | |
CN111329870B (zh) | Yadanzigan在制备治疗和/或预防肺损伤的药物中的用途 | |
CN103272083B (zh) | 用于预防和/或治疗哮喘的药物组合物、其制备方法及用途 | |
CN115804821A (zh) | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 | |
AU2006339963B2 (en) | Method and composition for treating allergic diseases | |
WO2022117004A1 (zh) | 间质性肺炎的治疗方法 | |
CN114668788A (zh) | 艾叶油包合物在制备治疗哮喘医用喷雾剂中的应用 | |
TWI480044B (zh) | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution | |
CN104302657B (zh) | 免疫调节胜肽用于治疗或预防发炎相关疾病的方法 | |
Blanco et al. | Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma | |
CN112245500B (zh) | 一种固肺中药组合物及其应用 | |
Zhang et al. | Effect of moxibustion at Feishu (BL 13) on airway inflammation in asthma model rats | |
Xiong et al. | [Retracted] Effect of Noninvasive Positive Pressure Ventilation on Prognosis and Blood Gas Level in COPD Patients Complicated with Respiratory Failure | |
CN114903941B (zh) | 陈皮醇提物及其在治疗嗜酸性粒细胞食管炎中的应用 | |
Ma et al. | Ding Chuan Tang Attenuates Airway Inflammation and Eosinophil Infiltration in Ovalbumin‐Sensitized Asthmatic Mice | |
CN114748465B (zh) | 一种用于治疗小儿哮喘的药物组合物及其用途 | |
CN114558066B (zh) | 一种用于治疗咳嗽变异性哮喘的药物组合物及其制备方法 | |
CN111184812B (zh) | 复方草石蚕颗粒慢性阻塞性肺疾病治疗药物制剂中的应用 | |
CN109394776B (zh) | 一种治疗弥漫性肺间质纤维化的中药组分方及其应用 | |
Wei et al. | Effect of kekeling mixture on the levels of IL-6 and IL-8 in RSV infected mice. | |
TWI631946B (zh) | 一種組合物用於製備預防或治療免疫過敏性呼吸道疾病的藥物的用途 | |
CN113599376A (zh) | 鸢尾甲黄素a在制备防治支气管哮喘疾病药物中的应用 | |
CN117100736A (zh) | 化合物ql-h008在制备肺部疾病防治药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Yin Hailong Inventor after: Song Fei Inventor after: Sun Tao Inventor after: Ma Wei Inventor after: Zhang Peng Inventor after: Yin Qiang Inventor after: Mu Dandan Inventor after: Fang Jinbo Inventor after: Tian Fang Inventor after: Zhou Qin Inventor after: Zhang Yali Inventor after: Peng Huiming Inventor after: Su Liyan, Sailimujiang Inventor before: Yin Hailong Inventor before: Ma Wei Inventor before: Zhang Peng Inventor before: Yin Qiang Inventor before: Mu Dandan Inventor before: Tian Fang Inventor before: Zhou Qin Inventor before: Zhao Yalin Inventor before: Su Liyan, Sailimujiang Inventor before: Song Fei Inventor before: Sun Tao |